Natco Pharma Ltd reports Q2 FY27 revenue of ₹1,019.4 crore, down 30.3% YoY, and PAT of ₹202.6 crore
- Revenue rose 28.3% sequentially; EBITDA was ₹310 crore, with a 30.4% margin including other income.
- PAT and share of associate profit fell 60.9% YoY and 1.9% sequentially; EPS was ₹11.31.
- Acquired an additional 13.25% stake in Adcock Ingram, taking its holding to 49%; invested a further US$16.7 million in eGenesis.
